These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 21095544)

  • 1. Circulating biomarkers in neuroendocrine tumors of the enteropancreatic tract: application to diagnosis, monitoring disease, and as prognostic indicators.
    Ardill JE; O'Dorisio TM
    Endocrinol Metab Clin North Am; 2010 Dec; 39(4):777-90. PubMed ID: 21095544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiopoietin-2 promotes disease progression of neuroendocrine tumors.
    Detjen KM; Rieke S; Deters A; Schulz P; Rexin A; Vollmer S; Hauff P; Wiedenmann B; Pavel M; Scholz A
    Clin Cancer Res; 2010 Jan; 16(2):420-9. PubMed ID: 20068079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.
    Lawrence B; Gustafsson BI; Kidd M; Pavel M; Svejda B; Modlin IM
    Endocrinol Metab Clin North Am; 2011 Mar; 40(1):111-34, viii. PubMed ID: 21349414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors.
    Singh S; Law C
    Expert Rev Gastroenterol Hepatol; 2012 Jun; 6(3):313-34. PubMed ID: 22646254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and predictive biomarkers in gastroenteropancreatic neuroendocrine tumors.
    Stevenson R; Libutti SK; Saif MW
    JOP; 2013 Mar; 14(2):155-7. PubMed ID: 23474561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours.
    Oberg K
    Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S17-25. PubMed ID: 22005113
    [No Abstract]   [Full Text] [Related]  

  • 7. Preface: Gastroenteropancreatic system and its tumors: Part 1.
    Vinik AI
    Endocrinol Metab Clin North Am; 2010 Dec; 39(4):xvii-xviii. PubMed ID: 21095538
    [No Abstract]   [Full Text] [Related]  

  • 8. Circulating angiopoietin-2 is elevated in patients with neuroendocrine tumours and correlates with disease burden and prognosis.
    Srirajaskanthan R; Dancey G; Hackshaw A; Luong T; Caplin ME; Meyer T
    Endocr Relat Cancer; 2009 Sep; 16(3):967-76. PubMed ID: 19502452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Updates on Neuroendocrine Tumors From the Gastrointestinal and Pancreatobiliary Tracts.
    Kim JY; Hong SM
    Arch Pathol Lab Med; 2016 May; 140(5):437-48. PubMed ID: 27128301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors.
    Massironi S; Conte D; Sciola V; Spampatti MP; Ciafardini C; Valenti L; Rossi RE; Peracchi M
    Am J Gastroenterol; 2010 Sep; 105(9):2072-8. PubMed ID: 20372113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New and emerging syndromes due to neuroendocrine tumors.
    Vinik AI; Gonzales MR
    Endocrinol Metab Clin North Am; 2011 Mar; 40(1):19-63, vii. PubMed ID: 21349410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification.
    Klöppel G; Couvelard A; Perren A; Komminoth P; McNicol AM; Nilsson O; Scarpa A; Scoazec JY; Wiedenmann B; Papotti M; Rindi G; Plöckinger U; ;
    Neuroendocrinology; 2009; 90(2):162-6. PubMed ID: 19060454
    [No Abstract]   [Full Text] [Related]  

  • 13. Placental growth factor supports neuroendocrine tumor growth and predicts disease prognosis in patients.
    Hilfenhaus G; Göhrig A; Pape UF; Neumann T; Jann H; Zdunek D; Hess G; Stassen JM; Wiedenmann B; Detjen K; Pavel M; Fischer C
    Endocr Relat Cancer; 2013 Jun; 20(3):305-19. PubMed ID: 23463017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The diagnostic value of plasma chromogranin A in neuroendocrine tumors].
    Yang XO; Li JN; Qian JM; Yang H; Chen Q; Lu L
    Zhonghua Nei Ke Za Zhi; 2011 Feb; 50(2):124-7. PubMed ID: 21418832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathology reporting of neuroendocrine tumors: essential elements for accurate diagnosis, classification, and staging.
    Klimstra DS
    Semin Oncol; 2013 Feb; 40(1):23-36. PubMed ID: 23391110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours?
    Walter T; Chardon L; Chopin-laly X; Raverot V; Caffin AG; Chayvialle JA; Scoazec JY; Lombard-Bohas C
    Eur J Cancer; 2012 Aug; 48(12):1766-73. PubMed ID: 22133573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Foreword: Gastroenteropancreatic system and its tumors: Part 1.
    LeRoith D
    Endocrinol Metab Clin North Am; 2010 Dec; 39(4):xiii-xvi. PubMed ID: 21095537
    [No Abstract]   [Full Text] [Related]  

  • 18. Measuring the relationship of quality of life and health status, including tumor burden, symptoms, and biochemical measures in patients with neuroendocrine tumors.
    Vinik E; Silva MP; Vinik AI
    Endocrinol Metab Clin North Am; 2011 Mar; 40(1):97-109, viii. PubMed ID: 21349413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Neuroendocrine tumors of the gastroenteropancreatic system--reevaluation using the Capella classification].
    Brüwer M; Pahlov-Nejad T; Herbst H; Senninger N; Schürmann G
    Zentralbl Chir; 2003 Aug; 128(8):656-62. PubMed ID: 12931261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sporadically occurring functional pancreatic endocrine tumors: review of recent literature.
    Goldin SB; Aston J; Wahi MM
    Curr Opin Oncol; 2008 Jan; 20(1):25-33. PubMed ID: 18043253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.